What is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?
作者信息
Kalenderoğlu Koray, Çınar Tufan, Hayıroğlu Mert İlker
机构信息
Department of Cardiology, Health Sciences University, Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Hospital, İstanbul, Türkiye.
Department of Medicine, University of Maryland Midtown Campus, Baltimore, Maryland, USA.
出版信息
Anatol J Cardiol. 2025 May 26;29(8):448-9. doi: 10.14744/AnatolJCardiol.2025.5347.
Abstract
摘要
相似文献
1
What is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?小直径支架的2型糖尿病患者的最佳抗血小板治疗方案是什么？
Anatol J Cardiol. 2025 May 26;29(8):448-9. doi: 10.14744/AnatolJCardiol.2025.5347.
2
Reply to Letter to the Editor: "What Is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?".致编辑信件的回复：“2型糖尿病合并小直径支架患者的最佳抗血小板治疗方案是什么？”
Anatol J Cardiol. 2025 Jun 30;29(8):450-1. doi: 10.14744/AnatolJCardiol.2025.5348.
3
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.双联抗血小板治疗的疗程：针对2016年美国心脏病学会/美国心脏协会关于冠心病患者双联抗血小板治疗疗程重点更新指南的系统评价：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2016 Sep 6;134(10):e156-78. doi: 10.1161/CIR.0000000000000405. Epub 2016 Mar 29.
4
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.双联抗血小板治疗时间：2016 年 ACC/AHA 指南双联抗血小板治疗时间的聚焦更新：冠心病患者双联抗血小板治疗时间的临床实践指南——美国心脏病学会/美国心脏协会工作组报告。
J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.
5
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.冠状动脉支架植入术后2型糖尿病患者三联抗血小板治疗与双联抗血小板治疗的有效性和安全性比较：一项随机对照试验的系统评价和荟萃分析
BMC Cardiovasc Disord. 2015 Oct 9;15:118. doi: 10.1186/s12872-015-0114-1.
6
Polymer-free stents for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis.无聚合物支架经皮冠状动脉介入治疗糖尿病患者：系统评价和荟萃分析。
Future Cardiol. 2024;20(9):485-497. doi: 10.1080/14796678.2024.2370688. Epub 2024 Jul 9.
7
Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome.吲哚布芬与阿司匹林用于老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后的比较
BMC Cardiovasc Disord. 2025 Jul 7;25(1):495. doi: 10.1186/s12872-025-04843-0.
8
Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study.英国国家医疗服务体系（NHS）低热量饮食实施试点评估：一项联合开展的混合方法研究。
Health Soc Care Deliv Res. 2025 Jul;13(29):1-63. doi: 10.3310/MPRT2139.
9
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.冠状动脉支架治疗缺血性心脏病：一项快速系统评价
Health Technol Assess. 2000;4(23):1-153.
10
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.糖尿病患者与非糖尿病患者使用药物洗脱支架和裸金属支架的疗效比较：协作网络荟萃分析
BMJ. 2008 Aug 29;337:a1331. doi: 10.1136/bmj.a1331.
引用本文的文献
1
Reply to Letter to the Editor: "What Is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?".致编辑信件的回复：“2型糖尿病合并小直径支架患者的最佳抗血小板治疗方案是什么？”
Anatol J Cardiol. 2025 Jun 30;29(8):450-1. doi: 10.14744/AnatolJCardiol.2025.5348.
本文引用的文献
1
Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents.替格瑞洛与氯吡格雷在小直径支架植入术后2型糖尿病患者中1年临床结局的比较
Anatol J Cardiol. 2025 Jan 7;29(2):95-103. doi: 10.14744/AnatolJCardiol.2024.4603.
2
Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.急性冠脉事件后使用强效抗血小板药物的大出血风险：临床实践中 5116 例连续患者中替格瑞洛和氯吡格雷的比较。
J Am Heart Assoc. 2021 Apr 20;10(8):e019467. doi: 10.1161/JAHA.120.019467. Epub 2021 Apr 9.
3
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.氯吡格雷与替格瑞洛或普拉格雷在 70 岁或以上非 ST 段抬高型急性冠脉综合征患者中的比较（POPular AGE）：随机、开放标签、非劣效性试验。
Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1.
4
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.糖尿病和慢性肾脏病对急性冠状动脉综合征患者心血管结局和血小板 P2Y 受体拮抗剂作用的影响：来自 PLATO 试验的见解。
J Am Heart Assoc. 2019 Mar 19;8(6):e011139. doi: 10.1161/JAHA.118.011139.
5
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.替格瑞洛与氯吡格雷用于老年急性冠脉综合征患者的疗效比较：前瞻性随机血小板抑制与患者预后（PLATelet inhibition and patient Outcomes，PLATO）试验的一项子研究
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8. doi: 10.1161/CIRCOUTCOMES.111.964395.
6
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.替格瑞洛与氯吡格雷用于急性冠脉综合征患者的比较
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
Zotero 插件